NCT02113332View on ClinicalTrials.gov

Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Liraglutide

DRUG

Placebo

Trial Locations (14)

Unknown

Ängelholm Hospital, Ängelholm

Falu Hospital, Falun

Clicical Trial Center Sahlgrenska, Gothenburg

Halmstad Hospital, Halmstad

Öbacka Clinic, Härnösand

Helsingborg Hospital, Helsingborg

Lindsdals Health Center, Kalmar

Karlskoga Hospital, Karlskoga

Kristianstad Hospital, Kristianstad

Kungsbacka Hospital, Kungsbacka

Malmö University Hospital, Malmo

CityDiabetes Clinic, Stockholm

NU-Hospital Organization, Uddevalla

Värnamo Hospital, Värnamo

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Vastra Gotaland Region

OTHER_GOV

NCT02113332 - Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections | Biotech Hunter | Biotech Hunter